drugset / Trial / NCT00362960

Olmesartan Medoxomil and Diabetic Nephropathy

NCT00362960

Phase 3 Completed 300 enrolled Sankyo Pharma Gmbh
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy

Timeline

Start
2003-05
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified
Subject Olmesartan medoxomil Unknown